Dorsal Root Ganglion Stimulation for the Management of Painful Intractable Small Fibre Neuropathy:

NCT ID: NCT02435004

Last Updated: 2021-03-26

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-04-30
• Study Completion Date: 2023-04-30

Brief Summary

A prospective, single-arm, mono-centre pilot study to obtain preliminary information on the ability of Dorsal Root Ganglion Stimulation (DRGS) in alleviating the painful symptoms in patients with small fiber neuropathy (SFN).

Detailed Description

This study is a prospective, single-arm, mono-centre pilot study enrolling a maximum of 31 patients with SFN. All enrolled patients will receive a trial neurostimulation (TNS) lasting from 3 to 30 days and only patients with a positive result in terms of pain intensity reduction will be eligible for the implanted neurostimulation (INS) phase. The target number of patients eligible for INS is 10 and this population will be assessed for impact of DRGS on the neuropathic pain caused by SFN. The expected duration of patients participation will be 14 months. The rationale for this open label approach is that this is a novel technique for which pilot data with regard to applicability and efficacy have yet to be established. Data gathered in the study will provide preliminary data required to assess the feasibility of this intervention, to be used for possible future studies with a more rigorous methodological approach (i.e. controlled trial, randomized controlled trial).

Conditions

Neuropathy Small Fibre

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Spinal Modulation Axium™

Spinal Modulation Axium™: an external trial neurostimulator (TNS) is used for the trial period, followed by an implanted neurostimulator (INS) if the TNS is successful. The TNS and INS are a pacemaker-sized devices that send out mild electrical pulses. The stimulator contains a battery and electrical components. Both TNS and INS are constant voltage devices. The TNS is used first and is worn on the outside of the clothing. The INS is implanted under the skin and support:

Group Type: OTHER

Spinal Modulation Axium™

Intervention Type: DEVICE

The participants will undergo implantation of electrodes for stimulation of fuor dorsal ganglia (Spinal Modulation, Inc., Menlo Park, CA, USA). Each participant will have one to four electrodes positioned according to the individual distribution of pain in the extremities. After implantation the electrode will be connected to an external neurostimulator: Spinal Modulation Axium™ for 3-30 days to evaluate their effectiveness (test stimulation).

If during the trial treatment the pain will decrease significantly (> 50%) a neurostimulator will be 'implanted for the continuation of the permanent neurostimulation. The neurostimulator is implanted in the abdomen in a subcutaneous pocket.

Interventions

Spinal Modulation Axium™

The participants will undergo implantation of electrodes for stimulation of fuor dorsal ganglia (Spinal Modulation, Inc., Menlo Park, CA, USA). Each participant will have one to four electrodes positioned according to the individual distribution of pain in the extremities. After implantation the electrode will be connected to an external neurostimulator: Spinal Modulation Axium™ for 3-30 days to evaluate their effectiveness (test stimulation).

If during the trial treatment the pain will decrease significantly (> 50%) a neurostimulator will be 'implanted for the continuation of the permanent neurostimulation. The neurostimulator is implanted in the abdomen in a subcutaneous pocket.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• 18 years or older at inclusion
• Chronic, intractable painful SFN in the peripheral limbs during at least 12 months and a biopsy positive for SFN, with a chronic pain intensity of ≥ 6 on a Numeric Rating Scale (ranging from 0 to 10), for which previous drug therapy was unsuccessful
• Stable medication dosage in the 30 days prior to inclusion
• Stable pattern of neurological symptoms

Exclusion Criteria

• Known or suspected non-compliance
• Drug or alcohol abuse
• Pain predominantly in upper limbs
• Neuropathy or chronic pain in limbs of other origin than SFN
• Peripheral vascular disease
• Severe foraminal stenosis at the expected target level
• Coagulation disorders
• Known immune-deficiency
• Other significant concomitant diseases and any concomitant malignancies
• Presence of other indwelling devices

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ospedale Regionale di Lugano

OTHER

Sponsor Role: lead

Responsible Party

Eva Koetsier MD PhD LLM

MD PhD LLM

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

EOC Lugano

Lugano, Canton Ticino, Switzerland

Site Status: RECRUITING

Countries

Switzerland

Central Contacts

Eva Koetsier, MD PhD LLM

Role: CONTACT

eva.koetsier@eoc.ch

0041918119590

Paolo Maino, MD PhD

Role: CONTACT

paolo.maino@eoc.ch

0041918119590

Facility Contacts

Paolo Maino, MD

Role: primary

paolo.maino@eoc.ch

0041918117590

Eva Koetsier, MD

Role: backup

eva.koetsier@eoc.ch

0041918117590

References

Koetsier E, Vacchi E, Maino P, Dukanac J, Melli G, van Kuijk SMJ. Dorsal Root Ganglion Stimulation in Chronic Painful Polyneuropathy: A Potential Modulator for Small Nerve Fiber Regeneration. Neuromodulation. 2023 Dec;26(8):1772-1780. doi: 10.1016/j.neurom.2022.08.455. Epub 2022 Oct 1.

Reference Type: DERIVED

PMID: 36192280 (View on PubMed)

Other Identifiers

NSI-TD-002

Identifier Type: -

Identifier Source: org_study_id